Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nasdaq Biotechnology Ishares ETF
(NQ:
IBB
)
149.47
+1.95 (+1.32%)
Official Closing Price
Updated: 4:15 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nasdaq Biotechnology Ishares ETF
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
December 02, 2022
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs...
Via
TheNewswire.com
Topics
Stocks
Exposures
Product Safety
US Equities
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
December 02, 2022
By Faith Ashmore, Benzinga
Via
News Direct
Exposures
Product Safety
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Via
Benzinga
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
December 01, 2022
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption.
Via
Benzinga
Will The Dow Jones Continue Higher? Will The Nasdaq Follow?
November 29, 2022
It's been a volatile few weeks in the markets, and it can be hard to tell if we're currently in a risk-on or risk-off environment.
Via
Talk Markets
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
November 28, 2022
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.
Via
Talk Markets
Market Currents: Why Pick Stocks?
November 28, 2022
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...
Via
Talk Markets
Look Who’s Leading Now
November 01, 2022
All indexes are near either their 50 or 200 DMA’s as we head into the Fed’s announcement tomorrow.
Via
Talk Markets
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Can Biotech Stocks Continue Rallying In This Bear Market?
October 31, 2022
Via
Talk Markets
October Was Not So Scary After All - Things To Keep A Watch Out For
October 31, 2022
Via
Talk Markets
These 4 ETFs Feature on CNBC's 'Final Trades'
October 27, 2022
On CNBC’s “Halftime Report Final Trades,” JPMorgan Private Bank’s Anastasia Amoroso chose iShares iBoxx $ High Yield Corporate Bond ETF (NYSE: HYG), saying that she wanted &ldq
Via
Benzinga
Russell 2000: How Money Is Made And Lost In Small Caps
October 19, 2022
IWM is in a bearish phase along with the other indices, but recent price action has shown relative strength.
Via
Talk Markets
The Four Indices: Where Each Are In A 4-Year Cycle
October 19, 2022
In the aftermath of last week’s market plunge and continued rally since, it is worth noting that the 200-week historic weekly support levels held for the SPY and the DIA, both of which were in danger...
Via
Talk Markets
Steady As She Goes With Healthcare Stocks
October 17, 2022
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports.
Via
Talk Markets
Precarious Action In The Bonds And Stock Market
October 16, 2022
Analysts and researchers claimed that double thrusts in the market have always preceded positive returns. Always, huh?
Via
Talk Markets
Taking The Temperature Of The Major Sector ETFs
October 12, 2022
One of the most important first steps towards trading success is to tilt your trading towards trending sectors that display strength and avoid market weakness.
Via
Talk Markets
3 Technical Lessons On Whether Or Not Semiconductors Bottomed
October 03, 2022
The semis ETF SMH has three interesting technical features that are a reliable way to assess what to do from here and how to know if this rally will last.
Via
Talk Markets
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
September 27, 2022
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market.
Via
InvestorPlace
Step Back To The Monthly Chart On Transportation
September 26, 2022
The chart of IYT is a perfect example of the monthly moving average and what to watch for.
Via
Talk Markets
Can Healthcare Stocks Continue To Outperform?
September 26, 2022
Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis.
Via
Talk Markets
The Biotech Sector Should Come Back First
September 25, 2022
We are looking for profitable opportunities to deploy dry powder. Many areas of biotech show incredible promise, including regenerative medicine, gene therapy, genomics, new advances in treating cancer...
Via
Talk Markets
The Major Sector ETFs Reveal All For Investors
September 06, 2022
Semiconductors have been a significant drag on Wall Street.
Via
Talk Markets
Healthcare Sector Still Looks Good But Lacks Momentum
September 06, 2022
The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...
Via
Talk Markets
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
Potential Signs That Could Derail The Economy
August 21, 2022
The last six weeks have brought a partial market recovery. Most of the media and financial reporters have been telling us how much better everything now seems.
Via
Talk Markets
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.